Panel Discussion: The Evolution of Development & Use Beyond Breast Cancer
Time: 10:00 am
day: Day One
Details:
• Sharing insights into future directions and what to anticipate as standards evolve for HER2 drugs in the clinic
• Addressing current treatment regimes and rational order of therapy
• Delving into combination thoughts and current status
• Understanding the current pitfalls in sequencing and selecting patients: how is HER2 high vs HER2 low
evolving?
• Exploring potency, side effects, efficacy ratios and discussing how we can better connect pre-clinic to the clinic
• Overviewing the status of Gastric, CRC, Biliary, Bladder, NSCLC, CNS, paediatric and other relevant tumor indications
• Defining the conventional targeting and novel approaches in terms of efficacy and use
Speakers:
Paul is a noted scientist and biotechnology executive with strong strategic and leadership experience. His industry expertise covers bench to IND and clinical trial development of small molecule drugs, biologics, and cellular therapeutics. His recent accomplishments include the launch of successful new biotech companies. In 2012 he engaged in the strategic analysis of cancer immuno-therapeutics…Read more